Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 7:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dry Mouth Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Rheumatology Patient Registry and Biorepository

NCT04402086
View directory record Official record
Conditions
Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 17, 2026, 7:42 AM EDT
Terminated Phase 2 Interventional Results available

Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects

NCT01316770
View directory record Official record
Conditions
Sjögren's Syndrome, Xerostomia
Interventions
Dexamethasone Parotid Irrigation, Placebo Parotid Irrigation
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Phase 3 Interventional Results available

Endometrial Safety Study

NCT00522873
View directory record Official record
Conditions
Postmenopause
Interventions
0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella)
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Chandler, Arizona • San Diego, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Sep 17, 2026, 7:42 AM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow-Up Study of AAV2hAQP1 for Radiation Induced Xerostomia

NCT05060341
View directory record Official record
Conditions
Radiation-induced Xerostomia
Interventions
Not listed
Lead sponsor
MeiraGTx, LLC
Industry
Eligibility
18 Years to 81 Years
Enrollment
22 participants
Timeline
2020 – 2027
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer

NCT00057785
View directory record Official record
Conditions
Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
Interventions
cisplatin, fluorouracil, Intensity modulated radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
17
States / cities
Birmingham, Alabama • Davis, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Phase 2 Interventional

Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors

NCT02150525
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I, Breast Cancer, Stage II, Breast Cancer, Stage III
Interventions
omega-3 fatty acid, placebo, Questionnaire administration
Dietary Supplement · Other · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 17, 2026, 7:42 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Comparative Autoantibody and Immunologic Cell Marker Study

NCT02422875
View directory record Official record
Conditions
Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prune Consumption and Bone Health in Young Women Using Hormonal Contraceptives

NCT04785131
View directory record Official record
Conditions
Osteoporosis Risk
Interventions
Prune
Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Not applicable Interventional

Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia

NCT04007081
View directory record Official record
Conditions
Xerostomia, Head and Neck Cancer
Interventions
Bone Marrow Aspiration, Ultrasound Imaging of Salivary Glands, Salivary Assay, Quality of Life Instruments
Procedure · Diagnostic Test · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 17, 2026, 7:42 AM EDT
Completed No phase listed Observational

Corneal Nerve Structure in Sjogren's

NCT03203382
View directory record Official record
Conditions
Sjogren's Syndrome, Vitamin D Deficiency
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Early Phase 1 Interventional

Preventive IVIG Therapy for Congenital Heart Block

NCT00460928
View directory record Official record
Conditions
Congenital Heart Block, Neonatal Lupus, Autoantibody-associated Heart Block
Interventions
intravenous immune globulin (IVIG)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Livingston, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 17, 2026, 7:42 AM EDT
Recruiting Not applicable Interventional

Study of Non-invasive Acupuncture-like Transcutaneous Electrical Nerve Stimulation (Altens) to Help Alleviate Xerostomia After Radiation Therapy for Cancers of the Head and Neck

NCT04805528
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Acupuncture-Like Transcutaneous Electrical Stimulation (ALTENS)
Radiation
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 17, 2026, 7:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ultrasound Evaluation of Tongue Movements in Speech and Swallowing

NCT00001167
View directory record Official record
Conditions
Otorhinolaryngologic Disease, Otorhinolaryngologic Neoplasm, Pharyngeal Neoplasm, Polymyositis, Speech Disorder
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
570 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1979 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Phase 1 Interventional

Omalizumab for Lupus

NCT01716312
View directory record Official record
Conditions
Systemic Lupus Erthematosus, Sjogren's Syndrome
Interventions
Omalizumab
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)

NCT04572841
View directory record Official record
Conditions
Sjögren's Syndrome, Sjogren's Syndrome
Interventions
SAR441344, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
DeBary, Florida • Duncansville, Pennsylvania • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Phase 2 Interventional

Etanercept Therapy for Sjogren's Syndrome

NCT00001954
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Etanercept
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Phase 2 Interventional

Randomized Amifostine For SCCHN

NCT00095927
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis, Radiation Toxicity, Xerostomia
Interventions
Amifostine, Carboplatin, Paclitaxel, radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
9
States / cities
Sanford, Maine • Boston, Massachusetts • Concord, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax

NCT02322528
View directory record Official record
Conditions
Sjogren's Disease
Interventions
Administration of Lotemax
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Sep 17, 2026, 7:42 AM EDT
Completed No phase listed Observational Results available

LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies

NCT02699190
View directory record Official record
Conditions
Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts 1, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus-Merzbacher-Like Disease, 1, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 18 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 17, 2026, 7:42 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

NCT07404865
View directory record Official record
Conditions
Primary Sjogren's Disease
Interventions
Telitacicept, Placebo
Biological · Drug
Lead sponsor
Vor Biopharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
43
States / cities
Chandler, Arizona • Flagstaff, Arizona • Glendale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 17, 2026, 7:42 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Sjogrens Syndrome Measured by Ultrasound

NCT03411850
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Orencia, Placebo
Biological · Other
Lead sponsor
Arthritis & Rheumatism Associates, P.C.
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions

NCT01903122
View directory record Official record
Conditions
Dry Mouth
Interventions
Cevimeline
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 17, 2026, 7:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fasting Conditions

NCT00602524
View directory record Official record
Conditions
Dry Mouth
Interventions
Pilocarpine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 17, 2026, 7:42 AM EDT
Recruiting Not applicable Interventional

Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders

NCT07180537
View directory record Official record
Conditions
Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Psoriatic Arthritis, Anxiety Disorders, Depressive Disorders, Moderate Depression, Moderate Anxiety
Interventions
Creating Health Online Course, Delayed access to Creating Health Online Course
Behavioral
Lead sponsor
Terry L. Wahls
Other
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 17, 2026, 7:42 AM EDT